Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT02715856 Terminated - Bone Metastases Clinical Trials

Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases

Start date: April 13, 2016
Phase: N/A
Study type: Interventional

This randomized pilot trial studies telemonitoring after surgery to preserve limb function in optimizing mobility in cancer survivors with cancer spread to the bone. The use of mobile devices for telemonitoring may improve the delivery of cost-effective, high-quality, standardized surveillance of cancer survivors.

NCT ID: NCT02715102 Terminated - Lung Cancer Clinical Trials

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Start date: June 2016
Phase: N/A
Study type: Observational

Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the utility of molecular diagnostic assays for the early detection of lung cancer.

NCT ID: NCT02714049 Terminated - Clinical trials for Hypoactive Sexual Desire Disorder

Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy

Start date: January 25, 2017
Phase: Phase 4
Study type: Interventional

Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.

NCT ID: NCT02713828 Terminated - Clinical trials for Squamous Cell Carcinoma of the Lung

Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung

PrE0504
Start date: April 10, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcinoma (SCC) of the lung who have failed a prior platinum-based chemotherapy regimen will receive glembatumumab vedotin. Glembatumumab vedotin consists of an antibody (a type of human protein) attached to a drug called Monomethyl Auristatin E (MMAE) that can kill cancer cells. Glembatumumab vedotin is intended to work by specifically directing the drug to the cancer cell. It attaches to a molecule on the cancer cell called gpNMB, and then releases the MMAE inside the tumor cell, which in turn causes the cell to die. The purpose of this study is to see whether glembatumumab vedotin is effective in treating people who have advanced or metastatic squamous cell lung cancer that contains gpNMB, to examine how the body handles the drug and the side effects associated with glembatumumab vedotin.

NCT ID: NCT02713633 Terminated - Clinical trials for Ureteropelvic Junction Obstruction

Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty

Start date: January 2016
Phase: N/A
Study type: Interventional

This prospective study, Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty will consist of four steps: 1.) Enrolling subjects in the study and signing the consent form 2.) Randomly divide subjects into 2 groups, group 1 will have internal stent and group 2 will have external stent 3.) At the time of stent removal in the clinic or in the OR subjects parents/ subjects will fill a questionnaire about pain after the procedure, stent care and stent tolerance and 4) Data from the questionnaires and procedure cost will be collected and all the data will be analyzed

NCT ID: NCT02712905 Terminated - Clinical trials for Solid Tumors and Hematologic Malignancy

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Start date: May 5, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 (dose expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the selected monotherapy dose(s) in AML/MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability, efficacy, PK, and PD of the selected combination dose(s) in Part 3.

NCT ID: NCT02711735 Terminated - Clinical trials for Tuberculosis, Multidrug Resistant

Safety of RUTI® Vaccination in MDR-TB Patients

Start date: March 18, 2020
Phase: Phase 2
Study type: Interventional

Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIa trial to evaluate safety and immunogenicity of RUTI® vaccine in Multidrug-resistant Tuberculosis (MDR-TB) patients favourably responding to standard MDR-TB treatment. Time point of vaccination starts at 16 weeks upon start of standard MDR-TB treatment (cohort A), and if clinically safe as evaluated by an independent panel of experts (DSMB), another cohort of patients will be vaccinated at 2 weeks upon start of standard MDR-TB treatment (cohort B), All the patients will be followed up 8 weeks after vaccination.

NCT ID: NCT02710695 Terminated - Clinical trials for Orthopaedic Related Pain (Musculoskeletal Pain)

Pain in America: A Randomized Controlled Trial

Start date: March 2016
Phase: N/A
Study type: Interventional

Each day orthopaedic surgeons worldwide treat patients with musculoskeletal pain. But little evidence exists about orthopaedic patient understanding of the common methods of managing musculoskeletal pain. Therefore, it is our aim to determine which discussion method best improves patient comprehension of common methods of managing pain.

NCT ID: NCT02709889 Terminated - Glioblastoma Clinical Trials

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Start date: September 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

NCT ID: NCT02707276 Terminated - Clinical trials for Bipolar Depression Depressed Phase

LFMS: Initial Trial in Geriatric Bipolar Depression

LFMS
Start date: September 7, 2016
Phase: N/A
Study type: Interventional

The primary aim of this study is to assess the efficacy of Low Field Magnetic Stimulation (LFMS) in treating symptoms of depression and anxiety in older adults suffering from bipolar depression. The investigators also aim to assess any cognitive benefits from regular LFMS treatments in older adults suffering from bipolar depression.